AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21205384 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavones (ISO)
Number of subjects: 100
Study 21205384 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise and isoflavones (Ex+ISO)
Number of subjects: 100
Study 18753809 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of sleep, depression, late-life function and disability assessment
Number of subjects: 128
Study 16613341 — intervention group
Group type: EXPERIMENTAL
Intervention: Men with a history of sexually transmitted infections
Number of subjects: 39
Study 16613341 — intervention group
Group type: COMPARATOR
Intervention: Men without a history of sexually transmitted infections
Number of subjects: 39
Study 14600814 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 520
Study 14600814 — intervention group
Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 520
Study 10479237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting for 7-10 days followed by an individually adjusted, gluten-free, vegan diet for 3.5 months and then an individually adjusted lactovegetarian diet for 9 months
Number of subjects: 53
Study 10479237 — intervention group
Group type: COMPARATOR
Intervention: Control group following their usual omnivorous diet
Number of subjects: 53
Study 10479237 — intervention group
Group type: EXPERIMENTAL
Intervention: Vegetarian diet responders
Number of subjects: 53
Study 10479237 — intervention group
Group type: COMPARATOR
Intervention: Diet nonresponders and omnivores
Number of subjects: 53
Study 8566592 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication
Number of subjects: 0
Study 8566592 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid suppression
Number of subjects: 0
Study 8566592 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of H. pylori eradication and acid suppression
Number of subjects: 0
Study 8566592 — intervention group
Group type: COMPARATOR
Intervention: Ulcer healing
Number of subjects: 0
Study 1937545 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP plus oral lorazepam (1 mg/d)
Number of subjects: 25
Study 1937545 — intervention group
Group type: COMPARATOR
Intervention: MCP (0.5 mg/kg 6 hourly i.v.)
Number of subjects: 25
Study 7035638 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous alimentation with a solution containing carbohydrate as 50% glucose and 50% galactose
Number of subjects: 6
Study 7035638 — intervention group
Group type: COMPARATOR
Intervention: Control glucose period
Number of subjects: 6
Study 30408596 — intervention group
Group type: EXPERIMENTAL
Intervention: Real neurofeedback (n=25) with Amyg-EFP-neurofeedback sessions for five weeks
Number of subjects: 34
Study 30408596 — intervention group
Group type: EXPERIMENTAL
Intervention: Real neurofeedback (n=25)
Number of subjects: 34
Study 30408596 — intervention group
Group type: COMPARATOR
Intervention: Sham neurofeedback (n=9)
Number of subjects: 34
Study 27931142 — intervention group
Group type: EXPERIMENTAL
Intervention: Orafti® inulin‐type fructans (2g daily for 6 weeks)
Number of subjects: 22
Study 27931142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 22
Study 27387121 — intervention group
Group type: EXPERIMENTAL
Intervention: Stories intervention (viewing videos of African-American Veterans telling stories about successful hypertension management)
Number of subjects: 618
Study 27387121 — intervention group
Group type: EXPERIMENTAL
Intervention: Stories intervention
Number of subjects: 618
Study 25091463 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid orthotic
Number of subjects: 56
Study 25091463 — intervention group
Group type: COMPARATOR
Intervention: Semi-rigid orthotic
Number of subjects: 56
Study 21735216 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 m sprint
Number of subjects: 11
Study 21735216 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 m sprint
Number of subjects: 11
Study 21735216 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 m sprint
Number of subjects: 11
Study 19777799 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine supplementation at 0.1 g/kg‐wt
Number of subjects: 12
Study 19777799 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17907864 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Motivational Interviewing (GMI)
Number of subjects: 101
Study 17907864 — intervention group
Group type: COMPARATOR
Intervention: Therapist Attention Activity Control Group (TAAC)
Number of subjects: 101
Study 14987460 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia (n = 41, cooled to 32-33 degrees C for 24 or 48 hours)
Number of subjects: 68
Study 14987460 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group not specified)
Number of subjects: 68
Study 11407108 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycoprotein IIb/IIIa antagonists
Number of subjects: 0
Study 11407108 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular weight heparins
Number of subjects: 0
Study 9313596 — intervention group
Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 763
Study 8198055 — intervention group
Group type: EXPERIMENTAL
Intervention: MUFA-diet
Number of subjects: 0
Study 8198055 — intervention group
Group type: COMPARATOR
Intervention: SAFA-diet
Number of subjects: 0
Study 3067410 — intervention group
Group type: EXPERIMENTAL
Intervention: Allapinin
Number of subjects: 33
Study 3067410 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethacizine
Number of subjects: 33
Study 3067410 — intervention group
Group type: COMPARATOR
Intervention: Mexitil
Number of subjects: 33
Study 31075706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT), 12 sessions
Number of subjects: 137
Study 28162849 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief feedback version of Grassessment
Number of subjects: 287
Study 28162849 — intervention group
Group type: COMPARATOR
Intervention: Extended feedback version of Grassessment
Number of subjects: 287
Study 25491929 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 20
Study 25491929 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 20
Study 23656707 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose (50 g available carbohydrate)
Number of subjects: 20
Study 23656707 — intervention group
Group type: COMPARATOR
Intervention: White bread (50 g available carbohydrate)
Number of subjects: 20
Study 23656707 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oral glucose and white bread
Number of subjects: 20
Study 21942436 — intervention group
Group type: EXPERIMENTAL
Intervention: DHEA (50 mg oral daily)
Number of subjects: 24
Study 21942436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 19127191 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports club participation (SCP) defined as participation at least once a week
Number of subjects: 502
Study 19127191 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 502
Study 16895950 — intervention group
Group type: COMPARATOR
Intervention: T+DMPA (testosterone implant + depot medroxy progesterone acetate)
Number of subjects: 18
Study 16895950 — intervention group
Group type: EXPERIMENTAL
Intervention: T+DMPA+FSH (testosterone implant + depot medroxy progesterone acetate + follicle-stimulating hormone)
Number of subjects: 18
Study 16895950 — intervention group
Group type: EXPERIMENTAL
Intervention: T+DMPA+hCG (testosterone implant + depot medroxy progesterone acetate + human chorionic gonadotropin)
Number of subjects: 18
Study 15204675 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone taper regimen for short-term opioid detoxification
Number of subjects: 234
Study 15204675 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone taper regimen
Number of subjects: 234
Study 15204675 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-naloxone
Number of subjects: 234
Study 11556635 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecamylamine (2.5 to 7.5 mg/day)
Number of subjects: 61
Study 11556635 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 9260216 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for standardizing SCORAD scoring by non-expert investigators
Number of subjects: 817
Study 9260216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermatologically experienced physicians
Number of subjects: 817
Study 9260216 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dermatologically experienced physicians
Number of subjects: 817
Study 9260216 — intervention group
Group type: EXPERIMENTAL
Intervention: Training program for standardizing SCORAD scoring
Number of subjects: 817
Study 8498652 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (Groups 3 and 4)
Number of subjects: 155
Study 8498652 — intervention group
Group type: COMPARATOR
Intervention: Thiopental and enflurane (Group 1)
Number of subjects: 155
Study 8498652 — intervention group
Group type: EXPERIMENTAL
Intervention: d‐tubocurarine and succinylcholine (Group 2)
Number of subjects: 155
Study 8498652 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium (Group 5)
Number of subjects: 155
Study 3027905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg/d)
Number of subjects: 24
Study 3027905 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril plus Hydrochlorothiazide (HCTZ)
Number of subjects: 24
Study 3027905 — intervention group
Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 24
Study 3027905 — intervention group
Group type: COMPARATOR
Intervention: Atenolol plus Hydrochlorothiazide (HCTZ)
Number of subjects: 24
Study 2688075 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 30389316 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachable Moment Brief Intervention (TMBI) + Care as Usual (CAU)
Number of subjects: 0
Study 30389316 — intervention group
Group type: EXPERIMENTAL
Intervention: Teachable Moment Brief Intervention (TMBI)
Number of subjects: 0
Study 30389316 — intervention group
Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 0
Study 31581743 — intervention group
Group type: EXPERIMENTAL
Intervention: High green leafy vegetable (GLV) dietary intervention, one cooked cup equivalent daily for 4 weeks
Number of subjects: 50
Study 31581743 — intervention group
Group type: COMPARATOR
Intervention: Control period (delayed intervention)
Number of subjects: 50
Study 28213170 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 154
Study 28213170 — intervention group
Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 154
Study 28213170 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Mirtazapine + SSRIs)
Number of subjects: 154
Study 28213170 — intervention group
Group type: COMPARATOR
Intervention: SSRIs monotherapy
Number of subjects: 154
Study 28213170 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine add-on for SSRIs non-responders
Number of subjects: 154
Study 28213170 — intervention group
Group type: COMPARATOR
Intervention: SSRIs add-on for mirtazapine non-responders
Number of subjects: 154
Study 25835002 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 117
Study 25835002 — intervention group
Group type: COMPARATOR
Intervention: Verapamil SR
Number of subjects: 117
Study 23602242 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher glycemic load diet
Number of subjects: 82
Study 23602242 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher grain intake
Number of subjects: 82
Study 23602242 — intervention group
Group type: EXPERIMENTAL
Intervention: High dietary glycemic load (GL)
Number of subjects: 82
Study 21496149 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous (IV) insulin infusion
Number of subjects: 61
Study 21496149 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous insulin
Number of subjects: 61
Study 21496149 — intervention group
Group type: COMPARATOR
Intervention: Standard care (Control group)
Number of subjects: 61
Study 19954075 — intervention group
Group type: EXPERIMENTAL
Intervention: Domestic split influenza virus vaccine (study group)
Number of subjects: 606
Study 19954075 — intervention group
Group type: COMPARATOR
Intervention: Imported vaccine (control group 1)
Number of subjects: 606
Study 19954075 — intervention group
Group type: COMPARATOR
Intervention: Imported vaccine (control group 2)
Number of subjects: 606
Study 16714146 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise trained group (n=17)
Number of subjects: 29
Study 16714146 — intervention group
Group type: COMPARATOR
Intervention: Untrained control group (n=12)
Number of subjects: 29
Study 14660311 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam and topical lidocaine‐prilocaine cream (EMLA)
Number of subjects: 13
Study 14660311 — intervention group
Group type: COMPARATOR
Intervention: Ketamine and topical placebo cream
Number of subjects: 13
Study 11600472 — intervention group
Group type: COMPARATOR
Intervention: Control or untreated arms of randomised controlled trials for primary prevention of variceal haemorrhage
Number of subjects: 1475
Study 9211479 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin (0.03 mg/ml, 20 microliters applied topically for 30 min)
Number of subjects: 70
Study 9211479 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 70
Study 9211479 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin-induced mechanical hyperalgesia
Number of subjects: 70
Study 9211479 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin-induced hyperalgesia
Number of subjects: 70
Study 8484146 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive dynamic back exercises with hyperextension
Number of subjects: 62
Study 8484146 — intervention group
Group type: COMPARATOR
Intervention: Intensive dynamic back exercises without hyperextension
Number of subjects: 62
Study 8484146 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 8484146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperextension group
Number of subjects: 62
Study 8484146 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperextension exercises
Number of subjects: 62
Study 8484146 — intervention group
Group type: EXPERIMENTAL
Intervention: Training duration
Number of subjects: 62
Study 3628610 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 5 mg/70 kg
Number of subjects: 0
Study 3628610 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg/70 kg
Number of subjects: 0
Study 3628610 — intervention group
Group type: EXPERIMENTAL
Intervention: d-amphetamine 20 mg/70 kg
Number of subjects: 0
Study 3628610 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29713156 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrronium (IND/GLY) 110/50 µg
Number of subjects: 2159
Study 26566165 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated eccentric muscle actions at 60°·s
Number of subjects: 12
Study 26566165 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated eccentric muscle actions at 120°·s
Number of subjects: 12
Study 26566165 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated eccentric muscle actions at 180°·s
Number of subjects: 12
Study 26566165 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated eccentric muscle actions (all velocities)
Number of subjects: 12
Study 23937643 — intervention group
Group type: EXPERIMENTAL
Intervention: High levels of global self-disclosure reported by perceivers who valued relationships with targets.
Number of subjects: 0
Study 23937643 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived high levels of self-disclosure when targets were responsive.
Number of subjects: 0
Study 23937643 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceptions of low self-disclosure predicted decreased perceptions of diagnosticity of targets' behavior.
Number of subjects: 0
Study 23937643 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental manipulations in Studies 5 and 6.
Number of subjects: 0
Study 24082325 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga methods (pain-managing) for three months, eight 90-minute sessions per month
Number of subjects: 60
Study 24082325 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 60
Study 20716255 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once daily for 14 days
Number of subjects: 460
Study 20716255 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin 500 mg once daily plus metronidazole 500 mg twice daily for 14 days
Number of subjects: 460
Study 20716255 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 460
Study 20716255 — intervention group
Group type: COMPARATOR
Intervention: Levofloxacin plus metronidazole
Number of subjects: 460
Study 18259086 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum perforatum
Number of subjects: 39
Study 18259086 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 39
Study 18259086 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18259086 — intervention group
Group type: EXPERIMENTAL
Intervention: Early onset of clinical improvement (first 2 weeks)
Number of subjects: 39
Study 15804500 — intervention group
Group type: EXPERIMENTAL
Intervention: Myopic subjects
Number of subjects: 0
Study 15804500 — intervention group
Group type: COMPARATOR
Intervention: Normal-sighted subjects
Number of subjects: 0
Study 12450492 — intervention group
Group type: EXPERIMENTAL
Intervention: Depth ordering consistent with perceptual occlusion of static elements
Number of subjects: 0
Study 12450492 — intervention group
Group type: COMPARATOR
Intervention: Placing moving components behind static elements
Number of subjects: 0
Study 12450492 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced surface stimulus configuration
Number of subjects: 0
Study 10425379 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride
Number of subjects: 0
Study 10425379 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 0
Study 10425379 — intervention group
Group type: COMPARATOR
Intervention: Monte Carlo simulations
Number of subjects: 0
Study 7538238 — intervention group
Group type: EXPERIMENTAL
Intervention: Transurethral resection (TURP)
Number of subjects: 120
Study 7538238 — intervention group
Group type: COMPARATOR
Intervention: Incision of the prostate (TUIP)
Number of subjects: 120
Study 2290163 — intervention group
Group type: EXPERIMENTAL
Intervention: Subacromial injection of triamcinolone
Number of subjects: 0
Study 2290163 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac 50 mg TDS
Number of subjects: 0
Study 2290163 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6937514 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% SnF2 mouthrinse
Number of subjects: 400
Study 6937514 — intervention group
Group type: COMPARATOR
Intervention: 0.05% NaF mouthrinse (active control)
Number of subjects: 400
Study 31297583 — intervention group
Group type: EXPERIMENTAL
Intervention: ACL reconstruction with LEAT
Number of subjects: 125
Study 31297583 — intervention group
Group type: COMPARATOR
Intervention: ACL reconstruction alone
Number of subjects: 125
Study 30107904 — intervention group
Group type: COMPARATOR
Intervention: 1 to 7 drinks/week
Number of subjects: 6083
Study 30107904 — intervention group
Group type: COMPARATOR
Intervention: 8 to 14 drinks/week
Number of subjects: 6083
Study 30107904 — intervention group
Group type: COMPARATOR
Intervention: >14 drinks/week
Number of subjects: 6083
Study 26784323 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque; n = 6)
Number of subjects: 12
Study 26784323 — intervention group
Group type: COMPARATOR
Intervention: Iohexol (Omnipaque; n = 6)
Number of subjects: 12
Study 26784323 — intervention group
Group type: EXPERIMENTAL
Intervention: Both Iodixanol and Iohexol
Number of subjects: 12
Study 26784323 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol
Number of subjects: 12
Study 26784323 — intervention group
Group type: COMPARATOR
Intervention: Iohexol
Number of subjects: 12
Study 25045936 — intervention group
Group type: EXPERIMENTAL
Intervention: Three whole eggs per day (EGG)
Number of subjects: 37
Study 25045936 — intervention group
Group type: COMPARATOR
Intervention: Yolk-free egg substitute (SUB)
Number of subjects: 37
Study 22086300 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 μg vitamin D(3) plus 1,000 mg calcium per day
Number of subjects: 45
Study 22086300 — intervention group
Group type: COMPARATOR
Intervention: 1,000 mg calcium per day (Control)
Number of subjects: 45
Study 19292654 — intervention group
Group type: EXPERIMENTAL
Intervention: Bofu‐tsusho‐san (BTS) 7.5 g/day
Number of subjects: 18
Study 19292654 — intervention group
Group type: COMPARATOR
Intervention: Placebo of BTS 7.5 g/day
Number of subjects: 18
Study 19292654 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E 500 mg and Vitamin C 1000 mg/day
Number of subjects: 18
Study 17485599 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium feeding (51.3 mmol per day)
Number of subjects: 1906
Study 17485599 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium feeding (307.8 mmol per day)
Number of subjects: 1906
Study 17485599 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium plus potassium supplementation (60 mmol per day)
Number of subjects: 1906
Study 17485599 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium
Number of subjects: 1906
Study 17485599 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium
Number of subjects: 1906
Study 17485599 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplementation
Number of subjects: 1906
Study 15170412 — intervention group
Group type: EXPERIMENTAL
Intervention: Home exercise program
Number of subjects: 43
Study 15170412 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient exercise program
Number of subjects: 43
Study 11594439 — intervention group
Group type: EXPERIMENTAL
Intervention: Enadoline (160 microg/70 kg)
Number of subjects: 6
Study 11594439 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone (1.5, 3, and 6 mg/70 kg)
Number of subjects: 6
Study 11594439 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol (1.5, 3, 6, and 12 mg/70 kg)
Number of subjects: 6
Study 9659646 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous CO2/O2 monitoring
Number of subjects: 0
Study 9659646 — intervention group
Group type: COMPARATOR
Intervention: Nonmonitored infants
Number of subjects: 0